Graphic representation of pharmacology: Development of an alternative model

Mental Health Clinician

Volumn 7, Issue 5, 2017, Pages 201-206

  Saklad, Stephen R ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

antipsychotics; aripiprazole; asenapine; brexpiprazole; cariprazine; chlorpromazine; clozapine; dopamine; fluphenazine; functional activity; graphic comparison; haloperidol; histamine; iloperidone; loxapine; lurasidone; model; molindone; norepinephrine; olanzapine; paliperidone; perphenazine; pharmacology; pimavanserin; psychotropics; quetiapine; receptor binding; risperidone; serotonin; ziprasidone

Indexed keywords

EID: 85055401763     PISSN: None     EISSN: 21689709     Source Type: Journal    
DOI: 10.9740/mhc.2017.09.201     Document Type: Article

References (14)

1. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, XXXVIII: update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55(4):597-606. DOI: 10.1124/pr.55.4.4. PubMed PMID: 14657418.
2. Strange PG. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol. 2009; 153(7):1353-63. DOI: 10.1038/sj.bjp.0707672. PubMed PMID: 18223670.
3. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2006; 320(1):1-13. DOI: 10.1124/jpet.106.104463. PubMed PMID: 16803859.
4. Box GEP, Draper NR. Empirical model-building and response surfaces. Hoboken: Wiley; 1987.
5. Baulieu EE, Raynaud JP. A ‘‘proportion graph’’ method for measuring binding systems. Eur J Biochem. 1970;13(2):293-304. DOI: 10.1111/j.1432-1033.1970.tb00931.x. PubMed PMID: 5439934.
6. Sumiyoshi T. Possible dose-side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia. Expert Rev Clin Pharmacol. 2008;1(6):791-802. DOI: 10.1586/ 17512433.1.6.791. PubMed PMID: 24410608.
7. Stahl SM. Stahl’s illustrated antipsychotics. 2nd ed. New York: Cambridge University Press; 2010.
8. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012;492(7428):215-20. DOI: 10.1038/ nature11691. PubMed PMID: 23235874.
9. Kroeze WK, Sassano MF, Huang XP, Lansu K, McCorvy JD, Giguère PM, et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat Struct Mol Biol. 2015;22(5):362-9. DOI: 10.1038/nsmb.3014. PubMed PMID: 25895059.
10. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911-36. DOI: 10.2165/00023210-200721110-00004. PubMed PMID: 17927296.
11. Krider RE, Raghubir P, Krishna A. Pizzas - p or square - psychophysical biases in area comparisons. Mark Sci. 2001;20(4): 405-25.
12. Sapp M, Gillan DJ. Length and area estimation with visual and tactile stimuli. Human Factors and Ergonomics Society Proceedings. 2004;48(16):1875-9.
13. Hall DA, Strange PG. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol. 1997;121(4):731-6. DOI: 10.1038/sj.bjp.0701196. PubMed PMID: 9208141.
14. Nutt D, Stahl S, Blier P, Drago F, Zohar J, Wilson S. Inverse agonists–what do they mean for psychiatry? Eur Neuropsychopharmacol. 2017;27(1):87-90. DOI: 10.1016/j.euroneuro.2016.11. 013. PubMed PMID: 27955830.